Our FHCRC/UW CFAR proposal focuses on three major themes: preventing HIV-1 infection, eradication and co-morbidities. Basic research in each of these areas will require sophisticated immunologic assessments, for example, target cell identification/quantification (HIV prevention), vaccine-induced immune responses (HIV prevention), immune activation status (pathogenesis) and latent cell identification/quantification (eradication). The Immunology Core will offer to all CFAR investigators innovative new and cutting-edge technologies (e.g., CyTOF, digital drop PCR and Cyntellect LEAP for single cell analyses) to assess molecular and cellular immune phenotypes and functions in diverse tissue types. The Core will dedicate its primary effort on training new/early investigators to apply these technologies to address fundamental research in the three areas. In addition, the core proposes to expand its scope to mucosal immunology, non-human primate immunology and the immunology of co-infections, and Seattle experts in these areas will join our core. The focus on new technologies and the addition of new experts place the Immunology Core in a very strong position to facilitate basic research in the new focus areas. In addition, the Core will continue to provide access to the humoral and cellular assays and expertise that currently comprise our Core.
The overarching goal of the Immunology Core is to facilitate cutting-edge immunologic assessments of diverse biologic specimen types to answer basic science questions related to HIV prevention, eradication and co-morbidities.
|Coban, Hamza; Robertson, Kevin; Smurzynski, Marlene et al. (2017) Impact of aging on neurocognitive performance in previously antiretroviral-naive HIV-infected individuals on their first suppressive regimen. AIDS 31:1565-1571|
|Goyette, Marielle S; Wilson, Kate S; Deya, Ruth et al. (2017) Brief Report: Association Between Menopause and Unprotected Sex in High-Risk HIV-Positive Women in Mombasa, Kenya. J Acquir Immune Defic Syndr 74:488-492|
|LaCourse, Sylvia M; Deya, Ruth W; Graham, Susan M et al. (2017) Evaluation of the Isoniazid Preventive Therapy Care Cascade Among HIV-Positive Female Sex Workers in Mombasa, Kenya. J Acquir Immune Defic Syndr 76:74-81|
|Dross, Sandra E; Munson, Paul V; Kim, Se Eun et al. (2017) Kinetics of Myeloid-Derived Suppressor Cell Frequency and Function during Simian Immunodeficiency Virus Infection, Combination Antiretroviral Therapy, and Treatment Interruption. J Immunol 198:757-766|
|Drozd, Daniel R; Saag, Michael S; Westfall, Andrew O et al. (2017) Comparative effectiveness of single versus multiple tablet antiretroviral therapy regimens in clinical HIV practice. Medicine (Baltimore) 96:e6275|
|Dombrowski, Julia C; Bove, Joanna; Roscoe, James C et al. (2017) ""Out of Care"" HIV Case Investigations: A Collaborative Analysis Across 6 States in the Northwest US. J Acquir Immune Defic Syndr 74 Suppl 2:S81-S87|
|Mugwanya, Kenneth K; John-Stewart, Grace; Baeten, Jared (2017) Safety of oral tenofovir disoproxil fumarate-based HIV pre-exposure prophylaxis use in lactating HIV-uninfected women. Expert Opin Drug Saf 16:867-871|
|Puttkammer, Nancy; Domerçant, Jean Wysler; Adler, Michelle et al. (2017) ART attrition and risk factors among Option B+ patients in Haiti: A retrospective cohort study. PLoS One 12:e0173123|
|Koelle, David M; Norberg, Peter; Fitzgibbon, Matthew P et al. (2017) Worldwide circulation of HSV-2?×?HSV-1 recombinant strains. Sci Rep 7:44084|
|Barbee, Lindley A; Khosropour, Christine M; Dombrowksi, Julia C et al. (2017) New Human Immunodeficiency Virus Diagnosis Independently Associated With Rectal Gonorrhea and Chlamydia in Men Who Have Sex With Men. Sex Transm Dis 44:385-389|
Showing the most recent 10 out of 1172 publications